All posts related to "JIA"

EULAR 2017 update on JIA: Never too young; Never too late

EULAR BannerAt this year’s annual EULAR 2017 annual congress, attendees learned about the need for increased collaboration between adult and paediatric rheumatologists to improve outcomes of adults living with active juvenile idiopathic arthritis (JIA).

According to conclusions from a review of more than 50 studies and approximately 3,000 JIA patients, half of adults living with JIA were not receiving adequate treatment, despite the fact that biological have been shown to improve the quality of life in children with JIA, with most of these benefits of treatment in childhood persisting into adulthood.

Presenting the results of her study, Dr. Berit Flato from the rheumatology department at Oslo University Hospital said: “Since 2000, biological and methotrexate have been prescribed earlier in JIA, resulting in increased rates of inactive disease after 1-3 years. Yet, recent reports indicate that only half of adult patients with JIA are on synthetic or biological disease-modifying anti-rheumatic drug (DMARDs).

The inadequate treatment identified in the study partly explains why adults with JIA often experience more pain, poorer health-related quality of life, and lower employment rates.

ACE Founder and President, Chery Koehn, related the study results to the Canadian environment: “The reasons why many adult patients with JIA in Canada fall through this treatment gaps are many. A large factor is the transition of children with JIA from paediatric care to adult care, which often is not as smooth as it should be.”

Cassie and Friends Banner for JIA
JIA affects approximately 24,000 children and teens in Canada, making it one of the most common causes of chronic disability in children. JIA can be devastating and comes with high financial, family and societal burdens. Approximately 60% of children will have active disease into childhood. For more information about JIA, please visit Cassie and Friends, the only charity in Canada dedicated 100# to the paediatric rheumatic disease community (Cassie & Friends).

Do it for the kids! Juvenile arthritis: Exercise, models of care, and advocacy

Four kids playing at the park

In honour of Juvenile Arthritis Awareness Month in Canada, we have compiled a list of interviews from this year’s CRA Annual Scientific Meeting & AHPA Annual Meeting in Ottawa. The interviews below highlight models of care, advocacy, clinical practices, and different therapy options for juvenile arthritis.  Continue reading

James Lowe: Winger defying arthritis for Super Rugby

James Lowe is a New Zealand rugby union player and an official ambassador for Arthritis New Zealand. Lowe plays in the wing position for the Markos and Chiefs. In 2014, he played his first Super Rugby and contributed to the Chiefs 18-10 victory over the Crusaders in Christchurch. His aim is to play for the Kiwi World Cup squad in the near future.

Lowe was diagnosed with juvenile rheumatoid arthritis, also known as juvenile idiopathic arthritis (JIA), at the young age of 14. He takes prescribed medications and a weekly injection to control his arthritis. JIA strikes children under the age of 16 and affects an estimated one in 1000 children.  It is one of the most common chronic diseases among children. To read about the different subtypes of juvenile idiopathic arthritis, please click here. Continue reading

Juvenile idiopathic arthritis: Depression linked to disease activity

A press release issued on June 9, 2016 by the European League Against Rheumatism Annual Congress highlighted a study that suggest depression is linked to disease activity and disability in adolescents with juvenile idiopathic arthritis. Below is a copy of the press release:

 

EULAR press conference slide

EULAR 2016

European League Against Rheumatism Annual Congress

London, United Kingdom, 8-11 June 2016

DEPRESSION LINKED TO DISEASE ACTIVITY AND DISABILITY IN ADOLESCENTS WITH ARTHRITIS
Study reinforces the importance of psychological assessment and support

London, United Kingdom, 9 June 2016: The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2016) confirmed a clear association between depression symptom severity and the level of disease activity and disability in adolescent patients with juvenile inflammatory arthritis (JIA). These findings highlight the importance of psychological health assessment for adolescents with JIA and underline the need for psychological support to be fully integrated into their routine care.

Let BC PharmaCare hear “Your Voice” on canakinumab

Megaphone GraphicBC PharmaCare is looking for your input on canakinumab for the treatment of systemic juvenile idiopathic arthritis (sJIA)

Canakinumab (Ilaris®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about canakinumab for the treatment of sJIA.

You can give input if you are a B.C. resident and have sJIA, a caregiver to someone with sJIA, or if your group represents people who live with sJIA.

The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process. Continue reading